Considerations and approach prior to treatment with 177Lutetium DOTATATE Radionuclide Therapy
S Huls, B Burkett, A Kendi, B Lunn, D Johnson… - 2022 - Soc Nuclear Med
2688 Introduction: 177Lutetium DOTATATE is the first FDA approved peptide receptor
radionuclide therapy (PRRT). It was approved in 2018 for the treatment of somatostatin …
radionuclide therapy (PRRT). It was approved in 2018 for the treatment of somatostatin …
Practical considerations for implementation of 177Lu-DOTATATE neuroendocrine tumor treatment programs
DK Soulek, ME Martin, NJ Mastascusa… - Journal of nuclear …, 2022 - Soc Nuclear Med
The 2018 Food and Drug Administration approval of 177Lu-DOTATATE for the treatment of
somatostatin receptor–positive neuroendocrine tumors (NETs) represents a paradigm …
somatostatin receptor–positive neuroendocrine tumors (NETs) represents a paradigm …
Lutetium-177 Dotatate Therapy, Revolutionizing the Way Somatostatin Receptor-Positive Neuroendocrine Tumors are Treated
A Cesko - 2020 - Soc Nuclear Med
3072 Objectives: The incidence of neuroendocrine tumors (NETs) has increased in
prevalence by 6-folds over the past 4 decades, becoming much more common than ever …
prevalence by 6-folds over the past 4 decades, becoming much more common than ever …
Guidance on 177Lu-DOTATATE peptide receptor radionuclide therapy from the experience of a single nuclear medicine division
A Abbott, CG Sakellis, E Andersen… - Journal of Nuclear …, 2018 - Soc Nuclear Med
177Lu-DOTATATE is a radiolabeled somatostatin analog that has been approved by the US
Food and Drug Administration (FDA) for the treatment of somatostatin receptor–positive …
Food and Drug Administration (FDA) for the treatment of somatostatin receptor–positive …
Ensuring Safe & Effective Delivery of Lutetium-177 Dotatate Therapy
R Fernandez, S Allen, V Lewington - 2015 - Soc Nuclear Med
479 Objectives This study, based on a large UK single-centre experience, considers a range
of scientific aspects which ensure safe delivery of 177 Lu-dotatate therapy. Methods 156 177 …
of scientific aspects which ensure safe delivery of 177 Lu-dotatate therapy. Methods 156 177 …
Nuts and bolts of 177Lu-DOTATATE administration in the nuclear medicine division: guidance from a single institute's experience
A Abbott, CG Sakellis, E Andersen… - Journal of Nuclear …, 2018 - Soc Nuclear Med
[Lutetium-177-DOTA (0), Tyr (3)] octreotate (177 Lu-DOTATATE) is a radiolabeled
somatostatin analog that has been approved by the US Food and Drug Administration for …
somatostatin analog that has been approved by the US Food and Drug Administration for …
Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors
AT Kendi, TR Halfdanarson, A Packard… - American Journal of …, 2019 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to enhance knowledge of the clinical
implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of …
implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of …
NANETS/SNMMI procedure standard for somatostatin receptor–based peptide receptor radionuclide therapy with 177Lu-DOTATATE
TA Hope, A Abbott, K Colucci, DL Bushnell… - Journal of Nuclear …, 2019 - Soc Nuclear Med
With the recent approval of 177Lu-DOTATATE for use in gastroenteropancreatic
neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing …
neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing …
[PDF][PDF] NANETS/SNMMI Procedure Guidelines for Somatostatin Receptor Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
TA Hope, A Abbott, K Colucci, DL Bushnell, L Gardner… - nanets.net
With the recent approval of 177 Lu‑DOTATATE for use in gastroenteropancreatic
neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing …
neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing …
Lutetium-177 DOTATATE: a practical review
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in
endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary …
endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary …